Coya Therapeutics' (NASDAQ:COYA – Get Rating) quiet period is set to end on Tuesday, February 7th. Coya Therapeutics had issued 3,050,000 shares in its IPO on December 29th. The total size of the offering was $15,250,000 based on an initial share price of $5.00. During Coya Therapeutics' quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

Separately, Chardan Capital initiated coverage on shares of Coya Therapeutics in a report on Thursday, January 26th. They issued a "buy" rating and a $9.00 price target on the stock.

Coya Therapeutics Stock Down 4.2 %

NASDAQ COYA opened at $4.35 on Tuesday. Coya Therapeutics has a 12 month low of $4.26 and a 12 month high of $5.67.

About Coya Therapeutics

Coya Therapeutics Inc is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

See Also

• Get a free copy of the StockNews.com research report on Coya Therapeutics (COYA)
• Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
• SoFi Technologies Smashes Earnings but Beware the Fed Decision
• Buying The Dip In Colgate-Palmolive
• Mullen Automotive On Hiring Spree, What Could That Mean?
• InterDigital Raises Its Earnings Guidance

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.